Teleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual Meeting - Seite 2

Clinical Study Presentation Information:

1. The Early Patient Experience Following Treatment With PUL and WVTT, Two Contemporary MISTs for BPH: Preliminary Results From the CLEAR Study; May 5, 7:00-9:00 AM, Room 303B
   This is a preliminary look at the CLEAR trial, the first head-to-head randomized controlled trial (RCT) comparing early patient outcomes after UroLift PUL and Rezūm Water Vapor Therapy (WVTT).⁵
   
   
2. Preliminary RCT Analysis of Minimally Invasive Surgery vs. Medication in the Initial Treatment of BPH-Associated LUTS; May 5, 1:24-1:32 PM, Stars at Night Ballroom
   IMPACT is the largest head-to-head RCT comparing minimally invasive surgical treatments (MISTs) to medication in the treatment of lower urinary tract symptoms (LUTS) secondary to BPH.⁶
   
   Real-world Evidence Study Presentation Information:
   
   
3. Real-World Analysis of Hospitalizations and Emergency Department Visits Following Surgical Treatments for Benign Prostatic Hyperplasia (BPH) Reveal Distinctions Between Minimally Invasive and Traditional Surgery; May 4, 7:00-9:00 AM, Room 221C
   This U.S. healthcare insurance claims analysis examines unplanned hospital admittance and emergency department visits that occurred within 30 days of the procedure. These events are often not reported in controlled trials but should be considered when evaluating BPH treatment options.⁷
   
   
4. Total Procedural Context Is Crucial in Understanding BPH Treatment Device Safety in the FDA’s MAUDE Database; May 5, 7:00-9:00 AM, Room 303B
   The FDA’s Manufacturer and User Facility Device Experience (MAUDE) database of medical device reports (MDRs) provides valuable information regarding safety and patient experience for BPH treatment devices. This analysis examines the number and severity of MDRs for BPH treatment devices in MAUDE and contextualizes those entries in the broader landscape of total procedures performed annually.⁸***
   
   
5. A US Healthcare Claims Analysis Reveals Post-surgery Medication Use Through 5 Years Is Similar Between PUL, TURP, and GreenLight; May 5, 3:30-5:30 PM, Room 304B
   Data are limited regarding medical therapy use following traditional surgical procedures and MISTs for BPH. In this large-scale, real-world analysis, rates of BPH medical therapy use are explored following transurethral resection of the prostate (TURP), GreenLight photovaporization of the prostate (PVP), and UroLift PUL procedures in a large database of U.S. healthcare claims.⁹

Teleflex is hosting two educational events: